Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional characterization.
autophagy
functional characterization
genetic variants
pancreatic cancer
polymorphisms
susceptibility
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
25 Sep 2024
25 Sep 2024
Historique:
revised:
17
07
2024
received:
04
04
2024
accepted:
26
08
2024
medline:
25
9
2024
pubmed:
25
9
2024
entrez:
25
9
2024
Statut:
aheadofprint
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with patients having unresectable or metastatic disease at diagnosis, with poor prognosis and very short survival. Given that genetic variation within autophagy-related genes influences autophagic flux and susceptibility to solid cancers, we decided to investigate whether 55,583 single nucleotide polymorphisms (SNPs) within 234 autophagy-related genes could influence the risk of developing PDAC in three large independent cohorts of European ancestry including 12,754 PDAC cases and 324,926 controls. The meta-analysis of these populations identified, for the first time, the association of the BID
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Czech Republic Ministry of Health
ID : GACR21-27902 and AZVNU21-03-00145
Organisme : "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo
Organisme : Consejería de Transformación Económica, Industria, Conocimiento y Universidades and FEDER
ID : PY20/01282
Organisme : Instituto de Salud Carlos III
ID : PI17/02256
Organisme : Instituto de Salud Carlos III
ID : PI20/01845
Organisme : Associazione Italiana Ricerca Cancro
ID : 26343
Organisme : National Institute for Cancer Research (Programme EXCELES)
ID : LX22NPO5102
Organisme : Charles University, Project GA UK No. 120
ID : UNCE/MED/006
Informations de copyright
© 2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.
Hu JX, Zhao CF, Chen WB, et al. Pancreatic cancer: a review of epidemiology, trend, and risk factors. World J Gastroenterol. 2021;27:4298‐4321.
Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:2140‐2141.
De La Cruz MS, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. Am Fam Physician. 2014;89:626‐632.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17‐48.
Simoes PK, Olson SH, Saldia A, Kurtz RC. Epidemiology of pancreatic adenocarcinoma. Chin Clin Oncol. 2017;6:24.
Lu Y, Gentiluomo M, Lorenzo‐Bermejo J, et al. Mendelian randomisation study of the effects of known and putative risk factors on pancreatic cancer. J Med Genet. 2020;57:820‐828.
Peduzzi G, Felici A, Pellungrini R, et al. Analysis of exposome and genetic variability suggests stress as a major contributor for development of pancreatic ductal adenocarcinoma. Dig Liver Dis. 2023;56:1054‐1063.
Galeotti AA, Gentiluomo M, Rizzato C, et al. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. J Med Genet. 2021;58:369‐377.
Pistoni L, Gentiluomo M, Lu Y, et al. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Carcinogenesis. 2021;42:1037‐1045.
Lu Y, Corradi C, Gentiluomo M, et al. Association of genetic variants affecting microRNAs and pancreatic cancer risk. Front Genet. 2021;12:693933.
Gentiluomo M, Canzian F, Nicolini A, Gemignani F, Landi S, Campa D. Germline genetic variability in pancreatic cancer risk and prognosis. Semin Cancer Biol. 2022;79:105‐131.
Nodari Y, Gentiluomo M, Mohelnikova‐Duchonova B, et al. Genetic and non‐genetic risk factors for early‐onset pancreatic cancer. Dig Liver Dis. 2023;55:1417‐1425.
Corradi C, Lencioni G, Gentiluomo M, et al. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. J Med Genet. 2023;60:980‐986.
Giaccherini M, Farinella R, Gentiluomo M, et al. Association between a polymorphic variant in the CDKN2B‐AS1/ANRIL gene and pancreatic cancer risk. Int J Cancer. 2023;153:373‐379.
Campa D, Matarazzi M, Greenhalf W, et al. Genetic determinants of telomere length and risk of pancreatic cancer: a PANDoRA study. Int J Cancer. 2019;144:1275‐1283.
Luo W, Tao J, Zheng L, Zhang T. Current epidemiology of pancreatic cancer: challenges and opportunities. Chin J Cancer Res. 2020;32:705‐719.
Nipp R, Tramontano AC, Kong CY, et al. Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Cancer Med. 2018;7:525‐535.
Yun Z, Zhichao J, Hao Y, et al. Targeting autophagy in multiple myeloma. Leuk Res. 2017;59:97‐104.
Dykstra KM, Allen C, Born EJ, Tong H, Holstein SA. Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Oncotarget. 2015;6:41535‐41549.
Garcia Ruiz O, Sanchez‐Maldonado JM, Lopez‐Nevot MA, et al. Autophagy in hematological malignancies. Cancers. 2022;14:14.
Eng CH, Wang Z, Tkach D, et al. Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy. Proc Natl Acad Sci U S A. 2016;113:182‐187.
Yang S, Wang X, Contino G, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011;25:717‐729.
Grasso D, Garcia MN, Iovanna JL. Autophagy in pancreatic cancer. Int J Cell Biol. 2012;2012:760498.
Dengjel J, Schoor O, Fischer R, et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci U S A. 2005;102:7922‐7927.
Yamamoto K, Venida A, Yano J, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC‐I. Nature. 2020;581:100‐105.
Gillson J, Abd El‐Aziz YS, Leck LYW, et al. Autophagy: a key player in pancreatic cancer progression and a potential drug target. Cancers. 2022;14:14.
Li J, Chen X, Kang R, Zeh H, Klionsky DJ, Tang D. Regulation and function of autophagy in pancreatic cancer. Autophagy. 2021;17:3275‐3296.
Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17:528‐542.
Levy JM, Thorburn A. Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther. 2011;131:130‐141.
Stromnes IM, DelGiorno KE, Greenberg PD, Hingorani SR. Stromal reengineering to treat pancreas cancer. Carcinogenesis. 2014;35:1451‐1460.
Zhang W, He R, Yang W, et al. Autophagic Schwann cells promote perineural invasion mediated by the NGF/ATG7 paracrine pathway in pancreatic cancer. J Exp Clin Cancer Res. 2022;41:48.
Gorgulu K, Diakopoulos KN, Ai J, et al. Levels of the autophagy‐related 5 protein affect progression and metastasis of pancreatic tumors in mice. Gastroenterology. 2019;156:203‐217.
Akar U, Ozpolat B, Mehta K, Fok J, Kondo Y, Lopez‐Berestein G. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol Cancer Res. 2007;5:241‐249.
Karasic TB, O'Hara MH, Loaiza‐Bonilla A, et al. Effect of gemcitabine and nab‐paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:993‐998.
Wolpin BM, Rubinson DA, Wang X, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014;19:637‐638.
Sainz J, Garcia‐Verdejo FJ, Martinez‐Bueno M, et al. Polymorphisms within autophagy‐related genes influence the risk of developing colorectal cancer: a meta‐analysis of four large cohorts. Cancers. 2021;13:1258.
Clavero E, Sanchez‐Maldonado JM, Macauda A, et al. Polymorphisms within autophagy‐related genes as susceptibility biomarkers for multiple myeloma: a meta‐analysis of three large cohorts and functional characterization. Int J Mol Sci. 2023;24:8500.
Kuballa P, Nolte WM, Castoreno AB, Xavier RJ. Autophagy and the immune system. Annu Rev Immunol. 2012;30:611‐646.
Jiang GM, Tan Y, Wang H, et al. The relationship between autophagy and the immune system and its applications for tumor immunotherapy. Mol Cancer. 2019;18:17.
Bakker OB, Aguirre‐Gamboa R, Sanna S, et al. Integration of multi‐omics data and deep phenotyping enables prediction of cytokine responses. Nat Immunol. 2018;19:776‐786.
Amundadottir L, Kraft P, Stolzenberg‐Solomon RZ, et al. Genome‐wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009;41:986‐990.
Petersen GM, Amundadottir L, Fuchs CS, et al. A genome‐wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 2010;42:224‐228.
Wolpin BM, Rizzato C, Kraft P, et al. Genome‐wide association study identifies multiple susceptibility loci for pancreatic cancer. Nat Genet. 2014;46:994‐1000.
Childs EJ, Mocci E, Campa D, et al. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nat Genet. 2015;47:911‐916.
Khurana E, Fu Y, Colonna V, et al. Integrative annotation of variants from 1092 humans: application to cancer genomics. Science. 2013;342:1235587.
Genomes Project Consortium, Abecasis GR, Auton A, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56‐65.
Romo L, Findlay SD, Burge CB. Regulatory features aid interpretation of 3'UTR variants. Am J Hum Genet. 2024;111:350‐363.
Das S, Forer L, Schonherr S, et al. Next‐generation genotype imputation service and methods. Nat Genet. 2016;48:1284‐1287.
Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome‐wide association studies. Nat Genet. 2006;38:904‐909.
Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta‐analysis of genomewide association scans. Bioinformatics. 2010;26:2190‐2191.
Manuel Sanchez‐Maldonado J, Martinez‐Bueno M, Canhao H, et al. NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: results from the REPAIR consortium. Sci Rep. 2020;10:4316.
Sanchez‐Maldonado JM, Cabrera‐Serrano AJ, Chattopadhyay S, et al. GWAS‐identified variants for obesity do not influence the risk of developing multiple myeloma: a population‐based study and meta‐analysis. Int J Mol Sci. 2023;24:6029.
Balduzzi S, Rucker G, Schwarzer G. How to perform a meta‐analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153‐160.
Li Y, Oosting M, Smeekens SP, et al. A functional genomics approach to understand variation in cytokine production in humans. Cell. 2016;167:1099‐1110.
Rios‐Tamayo R, Lupianez CB, Campa D, et al. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta‐analysis. Oncotarget. 2016;7:59029‐59048.
Westra HJ, Peters MJ, Esko T, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet. 2013;45:1238‐1243.
Xi H, Wang S, Wang B, et al. The role of interaction between autophagy and apoptosis in tumorigenesis (review). Oncol Rep. 2022;48:208.
Wang W, Li J, Tan J, et al. Endonuclease G promotes autophagy by suppressing mTOR signaling and activating the DNA damage response. Nat Commun. 2021;12:476.
Roos WP, Kaina B. DNA damage‐induced cell death by apoptosis. Trends Mol Med. 2006;12:440‐450.
Yeretssian G, Correa RG, Doiron K, et al. Non‐apoptotic role of BID in inflammation and innate immunity. Nature. 2011;474:96‐99.
Masson F, Kupresanin F, Mount A, Strasser A, Belz GT. Bid and Bim collaborate during induction of T cell death in persistent infection. J Immunol. 2011;186:4059‐4066.
Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res. 2016;44:D877‐D881.
Luo W, Li J, Zhang D, et al. Bid mediates anti‐apoptotic COX‐2 induction through the IKKbeta/NFkappaB pathway due to 5‐MCDE exposure. Curr Cancer Drug Targets. 2010;10:96‐106.
Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain‐only death agonist. Genes Dev. 1996;10:2859‐2869.
Zinkel SS, Ong CC, Ferguson DO, et al. Proapoptotic BID is required for myeloid homeostasis and tumor suppression. Genes Dev. 2003;17:229‐239.
Bertran‐Alamillo J, Gimenez‐Capitan A, Roman R, et al. BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors. Mol Cancer. 2023;22:110.
Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491‐501.
Lamparska‐Przybysz M, Gajkowska B, Motyl T. Cathepsins and BID are involved in the molecular switch between apoptosis and autophagy in breast cancer MCF‐7 cells exposed to camptothecin. J Physiol Pharmacol. 2005;56(Suppl 3):159‐179.
Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El‐Deiry WS. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol. 2002;4:842‐849.
Xu X, Qian D, Liu H, et al. Genetic variants in the liver kinase B1‐AMP‐activated protein kinase pathway genes and pancreatic cancer risk. Mol Carcinog. 2019;58:1338‐1348.
Chen F, Roberts NJ, Klein AP. Inherited pancreatic cancer. Chin Clin Oncol. 2017;6:58.
Katzke VA, Le Cornet C, Mahfouz R, et al. Are circulating immune cells a determinant of pancreatic cancer risk? A prospective study using epigenetic cell count measures. Cancer Epidemiol Biomarkers Prev. 2021;30:2179‐2187.
Liu C, Cheng H, Luo G, et al. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer. Int J Oncol. 2017;51:686‐694.
Cheng H, Luo G, Lu Y, et al. The combination of systemic inflammation‐based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Pancreatology. 2016;16:1080‐1084.
Ito Y, Takeda T, Wakasa K, Tsujimoto M, Sakon M, Matsuura N. Expression of p73 and p63 proteins in pancreatic adenocarcinoma: p73 overexpression is inversely correlated with biological aggressiveness. Int J Mol Med. 2001;8:67‐71.
Danilov AV, Neupane D, Nagaraja AS, et al. DeltaNp63alpha‐mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance. PLoS One. 2011;6:e26815.
Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. 2005;7:363‐373.
Rouschop KM, van den Beucken T, Dubois L, et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest. 2010;120:127‐141.
Zhang X, Lao M, Yang H, et al. Targeting cancer‐associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance. Autophagy. 2024;20:1314‐1334.
Omar N, Yan B, Salto‐Tellez M. HER2: an emerging biomarker in non‐breast and non‐gastric cancers. Pathogenesis. 2015;2:1‐9.
Meyers N, Gerard C, Lemaigre FP, Jacquemin P. Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma. Sci Rep. 2020;10:5241.
Ortega MA, Pekarek L, Fraile‐Martinez O, et al. Implication of ERBB2 as a predictive tool for survival in patients with pancreatic cancer in histological studies. Curr Oncol. 2022;29:2442‐2453.
Li Z, Shao C, Liu X, et al. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. Carcinogenesis. 2020;41:44‐55.
Shibata W, Kinoshita H, Hikiba Y, et al. Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice. Sci Rep. 2018;8:6150.
Gore J, Imasuen‐Williams IE, Conteh AM, Craven KE, Cheng M, Korc M. Combined targeting of TGF‐beta, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model. Cancer Lett. 2016;379:143‐153.
Stoecklein NH, Luebke AM, Erbersdobler A, et al. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J Clin Oncol. 2004;22:4737‐4745.
Aumayr K, Soleiman A, Sahora K, et al. HER2 gene amplification and protein expression in pancreatic ductal adenocarcinomas. Appl Immunohistochem Mol Morphol. 2014;22:146‐152.
Lin Y, Nakatochi M, Hosono Y, et al. Genome‐wide association meta‐analysis identifies GP2 gene risk variants for pancreatic cancer. Nat Commun. 2020;11:3175.
Campa D, Rizzato C, Capurso G, et al. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Dig Liver Dis. 2013;45:95‐99.
Campa D, Gentiluomo M, Stein A, et al. The PANcreatic Disease ReseArch (PANDoRA) consortium: ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Crit Rev Oncol Hematol. 2023;186:104020.